HC Wainwright reiterated their buy rating on shares of Antares Pharma (NASDAQ:ATRS) in a research report released on Wednesday. HC Wainwright currently has a $4.50 price objective on the specialty pharmaceutical company’s stock.
“Our $4.50 12-month target is based on a sum-of-the-parts after comprising $1.9/share for the other base-business, $0.7/share for other unapproved partnered pipeline, plus $0.3/share NOL’s, less $1.2/share un-allocated OPEX. above components is based on projected individual operating profits, after tax (at 25%), discounted back to 12-months from now at a 10.5% discount rate. We assume a fully-diluted share count of nearly 167M shares.”,” the firm’s analyst commented.
Several other equities analysts have also commented on the stock. Jefferies Financial Group increased their price objective on shares of Antares Pharma to $8.00 and gave the company a buy rating in a research report on Tuesday. BidaskClub lowered shares of Antares Pharma from a buy rating to a hold rating in a report on Friday, October 26th. Raymond James raised their target price on shares of Antares Pharma from $3.85 to $5.25 and gave the stock a strong-buy rating in a report on Tuesday, October 2nd. Piper Jaffray Companies restated a buy rating and issued a $4.00 target price on shares of Antares Pharma in a report on Friday, August 17th. Finally, ValuEngine upgraded shares of Antares Pharma from a hold rating to a buy rating in a report on Wednesday, August 8th. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. Antares Pharma currently has an average rating of Buy and a consensus price target of $5.44.
Antares Pharma (NASDAQ:ATRS) last released its quarterly earnings data on Tuesday, November 6th. The specialty pharmaceutical company reported ($0.01) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.02) by $0.01. Antares Pharma had a negative net margin of 27.84% and a negative return on equity of 56.80%. The business had revenue of $17.87 million during the quarter, compared to analyst estimates of $15.13 million. As a group, analysts anticipate that Antares Pharma will post -0.11 EPS for the current year.
In other news, Director Jacques Gonella sold 400,000 shares of the firm’s stock in a transaction dated Tuesday, October 2nd. The shares were sold at an average price of $3.79, for a total value of $1,516,000.00. Following the completion of the sale, the director now owns 9,585,848 shares in the company, valued at approximately $36,330,363.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Robert F. Apple sold 43,000 shares of the firm’s stock in a transaction dated Tuesday, August 21st. The stock was sold at an average price of $3.75, for a total transaction of $161,250.00. Following the completion of the sale, the chief executive officer now owns 1,573,562 shares of the company’s stock, valued at approximately $5,900,857.50. The disclosure for this sale can be found here. Insiders sold a total of 492,507 shares of company stock valued at $1,830,227 in the last 90 days. Company insiders own 12.20% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the company. MML Investors Services LLC lifted its holdings in shares of Antares Pharma by 92.4% in the 3rd quarter. MML Investors Services LLC now owns 40,600 shares of the specialty pharmaceutical company’s stock worth $136,000 after acquiring an additional 19,500 shares during the last quarter. Metropolitan Life Insurance Co. NY increased its stake in Antares Pharma by 127.0% in the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 51,612 shares of the specialty pharmaceutical company’s stock worth $133,000 after buying an additional 28,875 shares during the period. United Services Automobile Association increased its stake in Antares Pharma by 1,453.0% in the 2nd quarter. United Services Automobile Association now owns 405,261 shares of the specialty pharmaceutical company’s stock worth $21,147,000 after buying an additional 379,166 shares during the period. Perkins Capital Management Inc. increased its stake in Antares Pharma by 37.0% in the 3rd quarter. Perkins Capital Management Inc. now owns 435,000 shares of the specialty pharmaceutical company’s stock worth $1,462,000 after buying an additional 117,500 shares during the period. Finally, JPMorgan Chase & Co. increased its stake in Antares Pharma by 533.6% in the 1st quarter. JPMorgan Chase & Co. now owns 448,634 shares of the specialty pharmaceutical company’s stock worth $987,000 after buying an additional 377,824 shares during the period. Hedge funds and other institutional investors own 38.62% of the company’s stock.
Antares Pharma Company Profile
Antares Pharma, Inc, a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.
See Also: Outstanding Shares
Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.